Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZ3P6C)

Drug Name

Teplizumab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Type-1 diabetes	5A10	Approved	[1]
Melanoma	2C30	Phase 3	[2]

Cross-matching ID

TTD Drug ID: DMZ3P6C

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting T-cell surface glycoprotein CD3 gamma (CD3G)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tebentafusp	DMUJ1WV	Gastric cancer	2B72	Approved	[5]
Ertumaxomab	DM5Z3VP	Breast cancer	2C60-2C65	Phase 2	[6]
MGD007	DMAHWLR	Colorectal cancer	2B91.Z	Phase 1/2	[7]
MT-110	DMPCUN5	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
Autologous T-cell therapy	DMOAET3	Prostate cancer	2C82.0	Phase 1	[9]
MEDI-565	DMFWPLQ	Gastrointestinal cancer	2C11	Phase 1	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Drug(s) Targeting Regulatory protein unspecific (RGP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Visilizumab	DMXYM1H	Graft-versus-host disease	4B24	Phase 3	[10]
NI-0401	DMEOLVP	Autoimmune diabetes	5A10	Phase 1/2	[11]
MEDI-500	DMT3B4G	Bone marrow transplantation	QB63.6	Terminated	[12]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
T-cell surface glycoprotein CD3 (CD3)	TTUN7MC	NOUNIPROTAC	Inhibitor	[3]
Regulatory protein unspecific (RGP)	TTBMAOZ	NOUNIPROTAC	Not Available	[4]
T-cell surface glycoprotein CD3 gamma (CD3G)	TTV3XPL	CD3G_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

References

1	FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761183.
2	ClinicalTrials.gov (NCT00920582) Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus. U.S. National Institutes of Health.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF. Eur J Immunol. 2010 Oct;40(10):2891-901.
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs. 2012 Sep-Oct;4(5):614-22.
7	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
8	EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res. 2012 Jan 15;18(2):465-74.
9	Antitumor activities of PSMA CD3 diabodies by redirected T-cell lysis of prostate cancer cells. Immunotherapy. 2013 Jan;5(1):27-38.
10	Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways. Clin Immunol. 2008 Jun;127(3):322-9.
11	Clinical pipeline report, company report or official report of NovImmune.
12	T10B9 (MEDI-500) mediated immunosuppression: studies on the mechanism of action. Clin Transplant. 1996 Dec;10(6 Pt 2):607-13.